^
Association details:
| Biomarker: | BCR-ABL1 F359I |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Bosulif (bosutinib) (Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
Excerpt:
Responses were seen across Bcr-Abl mutations, including those associated with dasatinib and nilotinib resistance, except T315I. Bosutinib had an acceptable safety profile; treatment-emergent adverse events were primarily manageable grade 1/2 gastrointestinal events and rash. Grade 3/4 nonhematologic adverse events (> 2% of patients) included diarrhea (8%) and rash (4%). Bosutinib may offer a new treatment option for patients with chronic-phase CML after treatment with multiple TKIs. Table 4.....
DOI:
https://doi.org/10.1182/blood-2011-11-390120
Trial ID:
